Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

The Cumulative Dose But Not The Frequency Of Infusions Is a Risk Factor For The Development Of Osteonecrosis Of The Jaw (ONJ) In Myeloma Patients Who Receive Zoledronic Acid (ZA)

Efstathios Kastritis, Evangelos Terpos, Ioannis Melakopoulos, Pelagia Melea, Despoina Kalapanida, Maria Roussou, Maria Gavriatopoulou, Nikolaos Kanellias, Marina Iakovaki, Dimitrios Christoulas, Dimitra Gika, Meletios A. Dimopoulos, MD

Blood (2013) 122 (21): 3196.

https://doi.org/10.1182/blood.V122.21.3196.3196

Published: 2013

Journal Articles

Renal Impairment Is Not An Independent Adverse Prognostic Factor In Multiple Myeloma Patients Who Are Treated Upfront with Novel Agent-Based Regimens

Meletios A. Dimopoulos, Efstathios Kastritis, Maria Roussou, Maria Gavriatopoulou, Magdalini Migkou, Maria Gkotzamanidou, Marina Iakovaki, Charis Matsouka, Despina Mparmparousi, Nikitas Nikitas, Dimitra Gika, Irene Grapsa, Erasmia Psimenou, Evangelos Terpos

Blood (2010) 116 (21): 3033.

https://doi.org/10.1182/blood.V116.21.3033.3033

Published: 2010

Journal Articles

Short Progression Free Survival Predicts for Poor Overall Survival In Older Patients with Multiple Myeloma Treated Upfront with Novel Agent-Based Therapy

Efstathios Kastritis, Maria Roussou, Maria Gavriatopoulou, Magdalini Migkou, Maria Gkotzamanidou, Marina Iakovaki, Eleni Efstathiou, Evangelos Terpos, Meletios A. Dimopoulos

Blood (2010) 116 (21): 3035.

https://doi.org/10.1182/blood.V116.21.3035.3035

Published: 2010

Journal Articles

Increased levels of Vascular Cell Adhesion Molecule-1 (VCAM-1) and Inter-Cellular Adhesion Molecule-1 (ICAM-1) Correlate with Advanced Disease Features and Poor Survival in Newly Diagnosed Patients with Multiple Myeloma. Reduction Post-Bortezomib- and Lenalidomide-Based Regimens.

Magdalini Migkou, Evangelos Terpos, Dimitrios Christoulas, Maria Gavriatopoulou, Georgios Boutsikas, Maria Gkotzamanidou, Marina Iakovaki, Efstathios Kastritis, Athanasios Papatheodorou, Meletios A. Dimopoulos

Blood (2009) 114 (22): 1824.

https://doi.org/10.1182/blood.V114.22.1824.1824

Published: 2009

Journal Articles

Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma; Dosing of Lenalidomide According to Renal Function and Effect On Renal Impairment.

Meletios A. Dimopoulos, Dimitrios Christoulas, Maria Roussou, Efstathios Kastritis, Magdalini Migkou, Maria Gavriatopoulou, Maria Gkotzamanidou, Marina Iakovaki, Charis Matsouka, Despina Mparmparoussi, Erasmia Psimenou, Irini Grapsa, Eleni Efstathiou, Evangelos Terpos

Blood (2009) 114 (22): 3871.

https://doi.org/10.1182/blood.V114.22.3871.3871

Published: 2009

Journal Articles

Diffuse MRI Marrow Pattern Correlates with Increased Angiogenesis, Advanced Disease Features and Poor Prognosis in Newly-Diagnosed Patients with Multiple Myeloma Treated with Novel Agents.

Lia A. Moulopoulos, Evangelos Terpos, Dimitrios Christoulas, Efstathios Kastritis, Dimitra Anagnostou, Andreas Koureas, Maria Roussou, Maria Gavriatopoulou, Magdalini Migkou, Marina Iakovaki, Maria Gkotzamanidou, Vasilios Skiadas, Anna Tasidou, Meletios A. Dimopoulos

Blood (2009) 114 (22): 829.

https://doi.org/10.1182/blood.V114.22.829.829

Published: 2009

Journal Articles

Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or without Bortezomib: Prospective Evaluation of the Impact of Cytogenetic Abnormalities.

Meletios A. Dimopoulos, Efstathios Kastritis, Dimitrios Christoulas, Magdalini Migkou, Maria Gavriatopoulou, Maria Gkotzamanidou, Marina Iakovaki, Maria Roussou, Eleni Efstathiou, Evangelos Terpos

Blood (2009) 114 (22): 958.

https://doi.org/10.1182/blood.V114.22.958.958

Published: 2009

Journal Articles

The Addition of Bortezomib to the Combination of Lenalidomide and Dexamethasone Increases Bone Formation in Relapsed/Refractory Myeloma: a Prospective Study in 91 Patients.

Evangelos Terpos, Dimitrios Christoulas, Efstathios Kastritis, Maria Roussou, Maria Gavriatopoulou, Magdalini Migkou, Maria Gkotzamanidou, Marina Iakovaki, Athanasios Papatheodorou, Meletios A. Dimopoulos

Blood (2009) 114 (22): 1815.

https://doi.org/10.1182/blood.V114.22.1815.1815

Published: 2009

NARROW

The Cumulative Dose But Not The Frequency Of Infusions Is a Risk Factor For The Development Of Osteonecrosis Of The Jaw (ONJ) In Myeloma Patients Who Receive Zoledronic Acid (ZA)

Renal Impairment Is Not An Independent Adverse Prognostic Factor In Multiple Myeloma Patients Who Are Treated Upfront with Novel Agent-Based Regimens

Short Progression Free Survival Predicts for Poor Overall Survival In Older Patients with Multiple Myeloma Treated Upfront with Novel Agent-Based Therapy

Increased levels of Vascular Cell Adhesion Molecule-1 (VCAM-1) and Inter-Cellular Adhesion Molecule-1 (ICAM-1) Correlate with Advanced Disease Features and Poor Survival in Newly Diagnosed Patients with Multiple Myeloma. Reduction Post-Bortezomib- and Lenalidomide-Based Regimens.

Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma; Dosing of Lenalidomide According to Renal Function and Effect On Renal Impairment.

Diffuse MRI Marrow Pattern Correlates with Increased Angiogenesis, Advanced Disease Features and Poor Prognosis in Newly-Diagnosed Patients with Multiple Myeloma Treated with Novel Agents.

Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or without Bortezomib: Prospective Evaluation of the Impact of Cytogenetic Abnormalities.

The Addition of Bortezomib to the Combination of Lenalidomide and Dexamethasone Increases Bone Formation in Relapsed/Refractory Myeloma: a Prospective Study in 91 Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only